227 related articles for article (PubMed ID: 29794402)
1. Effects of Carperitide on Degree of Pulmonary Congestion in Treatment of Acute Heart Failure.
Kawase Y; Hata R; Tada T; Katoh H; Kadota K
Circ J; 2018 Jul; 82(8):2079-2088. PubMed ID: 29794402
[TBL] [Abstract][Full Text] [Related]
2. Rationale and Design of Low-dose Administration of Carperitide for Acute Heart Failure (LASCAR-AHF).
Nagai T; Honda Y; Nakano H; Honda S; Iwakami N; Mizuno A; Komiyama N; Yamane T; Furukawa Y; Miyagi T; Nishihara S; Tanaka N; Adachi T; Hamasaki T; Asaumi Y; Tahara Y; Aiba T; Sugano Y; Kanzaki H; Noguchi T; Kusano K; Yasuda S; Ogawa H; Anzai T
Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):551-557. PubMed ID: 29098501
[TBL] [Abstract][Full Text] [Related]
3. Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis.
Matsue Y; Kagiyama N; Yoshida K; Kume T; Okura H; Suzuki M; Matsumura A; Yoshida K; Hashimoto Y
J Card Fail; 2015 Nov; 21(11):859-64. PubMed ID: 25999241
[TBL] [Abstract][Full Text] [Related]
4. Effect of intravenous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure: Insight from a nationwide claim-based database.
Nagai T; Iwakami N; Nakai M; Nishimura K; Sumita Y; Mizuno A; Tsutsui H; Ogawa H; Anzai T;
Int J Cardiol; 2019 Apr; 280():104-109. PubMed ID: 30674432
[TBL] [Abstract][Full Text] [Related]
5. The impact of carperitide usage on the cost of hospitalization and outcome in patients with acute heart failure: High value care vs. low value care campaign in Japan.
Mizuno A; Iguchi H; Sawada Y; Hurley M; Nomura H; Hayashi K; Tokuda Y; Watanabe S; Yoshikawa A
Int J Cardiol; 2017 Aug; 241():243-248. PubMed ID: 28476514
[TBL] [Abstract][Full Text] [Related]
6. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).
Lala A; McNulty SE; Mentz RJ; Dunlay SM; Vader JM; AbouEzzeddine OF; DeVore AD; Khazanie P; Redfield MM; Goldsmith SR; Bart BA; Anstrom KJ; Felker GM; Hernandez AF; Stevenson LW
Circ Heart Fail; 2015 Jul; 8(4):741-8. PubMed ID: 26041600
[TBL] [Abstract][Full Text] [Related]
7. Effect of carperitide on the 1 year prognosis of patients with acute decompensated heart failure.
Nogi K; Ueda T; Matsue Y; Nogi M; Ishihara S; Nakada Y; Kawakami R; Kagiyama N; Kitai T; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Kida K; Okumura T; Saito Y
ESC Heart Fail; 2022 Apr; 9(2):1061-1070. PubMed ID: 35118813
[TBL] [Abstract][Full Text] [Related]
8. Comparison of salt with low-dose furosemide and carperitide for treating acute decompensated heart failure: a single-center retrospective cohort study.
Okuhara Y; Hirotani S; Ando T; Nishimura K; Orihara Y; Komamura K; Naito Y; Mano T; Masuyama T
Heart Vessels; 2017 Apr; 32(4):419-427. PubMed ID: 27469321
[TBL] [Abstract][Full Text] [Related]
9. Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure.
Kobayashi M; Watanabe M; Coiro S; Bercker M; Paku Y; Iwasaki Y; Chikamori T; Yamashina A; Duarte K; Ferreira JP; Rossignol P; Zannad F; Girerd N
Int J Cardiol; 2019 Aug; 289():91-98. PubMed ID: 30770263
[TBL] [Abstract][Full Text] [Related]
10. Effect of carperitide on in-hospital mortality of patients admitted for heart failure: propensity score analyses.
Ogiso M; Isogai T; Okabe Y; Ito K; Tsuji M; Tanaka H
Heart Vessels; 2017 Aug; 32(8):916-925. PubMed ID: 28220240
[TBL] [Abstract][Full Text] [Related]
11. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study.
Hata N; Seino Y; Tsutamoto T; Hiramitsu S; Kaneko N; Yoshikawa T; Yokoyama H; Tanaka K; Mizuno K; Nejima J; Kinoshita M
Circ J; 2008 Nov; 72(11):1787-93. PubMed ID: 18812677
[TBL] [Abstract][Full Text] [Related]
12. Predictors of a Good Diuretic Response and Administration Methods for Carperitide in Patients With Acute Heart Failure.
Inamoto M; Kohyama N; Suzuki H; Ebato M; Kogo M
Clin Ther; 2024 Jan; 46(1):12-19. PubMed ID: 37945501
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial.
Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y
Biomed Res Int; 2014; 2014():704289. PubMed ID: 25436213
[TBL] [Abstract][Full Text] [Related]
14. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study.
Nomura F; Kurobe N; Mori Y; Hikita A; Kawai M; Suwa M; Okutani Y
Circ J; 2008 Nov; 72(11):1777-86. PubMed ID: 18832779
[TBL] [Abstract][Full Text] [Related]
15. Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes.
Platz E; Campbell RT; Claggett B; Lewis EF; Groarke JD; Docherty KF; Lee MMY; Merz AA; Silverman M; Swamy V; Lindner M; Rivero J; Solomon SD; McMurray JJV
JACC Heart Fail; 2019 Oct; 7(10):849-858. PubMed ID: 31582107
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of the Severity of Clinical Congestion in Patients Hospitalized for Decompensated Heart Failure: Findings From the Japanese KCHF Registry.
Aida K; Nagao K; Kato T; Yaku H; Morimoto T; Inuzuka Y; Tamaki Y; Yamamoto E; Yoshikawa Y; Kitai T; Taniguchi R; Iguchi M; Kato M; Takahashi M; Jinnai T; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Su K; Kawato M; Seko Y; Inada T; Inoko M; Toyofuku M; Furukawa Y; Nakagawa Y; Ando K; Kadota K; Shizuta S; Ono K; Sato Y; Kuwahara K; Ozasa N; Kimura T
J Card Fail; 2023 Aug; 29(8):1150-1162. PubMed ID: 36690136
[TBL] [Abstract][Full Text] [Related]
17. Predictors of responders for low-dose carperitide monotherapy in patients with acute heart failure.
Kamiya M; Sato N; Matsuda J; Nozaki A; Akiya M; Sato T; Okazaki H; Takahashi Y; Shimizu W
Heart Vessels; 2020 Jan; 35(1):59-68. PubMed ID: 31227874
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of decreased peripheral congestion detected by Bioelectrical Impedance Vector Analysis (BIVA) in patients hospitalized for acute heart failure: BIVA prognostic value in acute heart failure.
Santarelli S; Russo V; Lalle I; De Berardinis B; Vetrone F; Magrini L; Di Stasio E; Piccoli A; Codognotto M; Mion MM; Castello LM; Avanzi GC; Di Somma S;
Eur Heart J Acute Cardiovasc Care; 2017 Jun; 6(4):339-347. PubMed ID: 27073131
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure.
Ishikawa C; Tsutamoto T; Wada A; Fujii M; Ohno K; Sakai H; Yamamoto T; Horie M
J Cardiovasc Pharmacol; 2005 Oct; 46(4):513-8. PubMed ID: 16160606
[TBL] [Abstract][Full Text] [Related]
20. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).
Ambrosy AP; Bhatt AS; Gallup D; Anstrom KJ; Butler J; DeVore AD; Felker GM; Fudim M; Greene SJ; Hernandez AF; Kelly JP; Samsky MD; Mentz RJ
Am J Cardiol; 2017 Jul; 120(1):98-105. PubMed ID: 28479167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
